Effect of delaying surgery by more than 10 weeks after neoadjuvant therapy in rectal cancer: a single institution experience

被引:1
|
作者
Piva, Cristina [1 ]
Suffat, Luca Panier [2 ]
Petrucci, Edoardo T. F. [3 ]
Manuguerra, Giovanna [4 ]
Vittone, Federico [5 ]
Cante, Domenico [1 ]
Ferrario, Silvia [1 ]
Paolini, Marina [1 ]
Radici, Lorenzo [3 ]
Vellani, Giorgio [4 ]
La Porta, Maria R. [1 ]
机构
[1] Ivrea Community Hosp, Dept Radiat Oncol, ASL TO4, Ivrea, Italy
[2] Ivrea Community Hosp, Dept Surg, ASL TO4, Piazza Credenza 2, I-10015 Ivrea, Italy
[3] Ivrea Community Hosp, Dept Med Phys, ASL TO4, Ivrea, Italy
[4] Ivrea Community Hosp, Dept Oncol, ASL TO4, Ivrea, Italy
[5] Ivrea Community Hosp, Dept Pathol, ASL TO4, Ivrea, Italy
关键词
Rectal cancer; Neoadjuvant chemoradiotherapy; Surgery; Time interval; PATHOLOGICAL COMPLETE RESPONSE; PREOPERATIVE CHEMORADIOTHERAPY; INTERVAL; MULTICENTER; SURVIVAL; CHEMORADIATION; CHEMOTHERAPY; OXALIPLATIN; TRIAL;
D O I
10.1007/s13304-021-01189-y
中图分类号
R61 [外科手术学];
学科分类号
摘要
The optimal timing of surgery after neoadjuvant chemoradiotherapy (CRT) in locally advanced rectal cancer is still controversial. Aim of this study was to evaluate the effect of increasing time interval between the end of CRT and surgery on pathological outcomes. This is a retrospective analysis on 114 patients treated with long-course neoadjuvant RT with or without chemotherapy between January 2005 and September 2020. 43 patients underwent surgery within 10 weeks from the end of CRT (1st group), whereas 71 patients underwent total mesorectal excision with a time interval equal or greater than 10 weeks (2nd group). Primary endpoint was pCR (pathological complete response). Secondary endpoints were near pCR (ypT0-1 N0), tumor downstaging (ypT less than cT), nodal downstaging (ypN less than cN), and overall response comparing clinical with pathological TN stage. Overall, the pCR rate was 8.8%, whereas we observed no significantly difference in primary endpoint between the two groups. Considering near pCR, a trend toward significant difference in favor of 2nd group was seen (p = 0.072). Tumor and nodal downstaging rates were 39.5%, 41.9%, 59.2%, and 56.3% in the 1st and 2nd group, respectively, with a statistically significant difference for T category (p = 0.042). Overall response rates (TN stage) showed a trend toward significant difference in favor of patients of the >= 10 week group (p = 0.059). Our study suggests that a prolonged time interval between the end of CRT and surgery (>= 10 weeks) increases pathological response rates.
引用
收藏
页码:145 / 151
页数:7
相关论文
共 50 条
  • [41] Neoadjuvant oxaliplatin and 5-fluorouracil with concurrent radiotherapy in patients with locally advanced rectal cancer: a single-institution experience
    Greto, D.
    Paiar, F.
    Saieva, C.
    Galardi, A.
    Mangoni, M.
    Livi, L.
    Agresti, B.
    Franceschini, D.
    Bonomo, P.
    Scotti, V.
    Detti, B.
    Tonelli, F.
    Valeri, A.
    Messerini, L.
    Biti, G.
    RADIOLOGIA MEDICA, 2013, 118 (04): : 570 - 582
  • [42] MRI is more accurate than FDG-PET in assessing complete response in rectal cancer patients after neoadjuvant therapy
    Yehuda Kariv
    Ronen Berkovitz
    Reut El-On
    Alexander Barenboim
    Hagit Tulchinsky
    Meir Zemel
    Oded Brautbar
    Dan Mirelman
    Sharon Pelles-Avraham
    Ravit Geva
    Inna Ospovat
    Guy Lahat
    Jonathan B. Yuval
    Langenbeck's Archives of Surgery, 410 (1)
  • [43] Outcome and Salvage Surgery Following "Watch and Wait" for Rectal Cancer after Neoadjuvant Therapy: A Systematic Review
    Kong, Joseph C.
    Guerra, Glen R.
    Warrier, Satish K.
    Ramsay, Robert G.
    Heriot, Alexander G.
    DISEASES OF THE COLON & RECTUM, 2017, 60 (03) : 335 - 345
  • [44] Effect of neoadjuvant therapy on textbook outcomes in minimally invasive rectal cancer surgery
    Zhang, Guiqi
    Pan, Shiquan
    Wei, Jiashun
    Rong, Jie
    Liu, Yuan
    Wu, Dongbo
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2025, 23 (01)
  • [45] Response to Neoadjuvant Systemic Therapy for Breast Cancer in BRCA Mutation Carriers and Noncarriers: A Single-Institution Experience
    Arun, Banu
    Bayraktar, Soley
    Liu, Diane D.
    Barrera, Angelica M. Gutierrez
    Atchley, Deann
    Pusztai, Lajos
    Litton, Jennifer Keating
    Valero, Vicente
    Meric-Bernstam, Funda
    Hortobagyi, Gabriel N.
    Albarracin, Constance
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (28) : 3739 - 3746
  • [46] Timing of Surgery and Social Determinants of Health Related to Pathologic Complete Response after Total Neoadjuvant Therapy for Rectal Adenocarcinoma: Retrospective Study of National Cancer Database
    Mai, Megan
    Goldman, Jodi
    Appiah, Duke
    Abdulrahman, Ramzi
    Kidwell, John
    Shi, Zheng
    CURRENT ONCOLOGY, 2024, 31 (03) : 1291 - 1301
  • [47] Clinical Effect of Radiotherapy Combined with Capecitabine after Neoadjuvant Therapy for Rectal Cancer
    Zhang, Qibo
    Teng, Haibin
    JOURNAL OF ONCOLOGY, 2021, 2021
  • [48] Is adjuvant chemotherapy necessary for patients with pathological complete response after neoadjuvant chemoradiotherapy and radical surgery in locally advanced rectal cancer? Long-term analysis of 40 ypCR patients at a single center
    Zhou, Jiaolin
    Qiu, Huizhong
    Lin, Guole
    Xiao, Yi
    Wu, Bin
    Wu, Wenming
    Sun, Xiyu
    Lu, Junyang
    Zhang, Guannan
    Xu, Lai
    Liu, Yuchao
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2016, 31 (06) : 1163 - 1168
  • [49] Standard (8 weeks) vs long (12 weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR)
    Monsellato, Igor
    Alongi, Filippo
    Bertocchi, Elisa
    Gori, Stefania
    Ruffo, Giacomo
    Cassinotti, Elisa
    Baldarti, Ludovica
    Boni, Luigi
    Pernazza, Graziano
    Pulighe, Fabio
    De Nisco, Carlo
    Perinotti, Roberto
    Morpurgo, Emilio
    Contardo, Tania
    Mammano, Enzo
    Elmore, Ugo
    Delpini, Roberto
    Rosati, Riccardo
    Perna, Federico
    Coratti, Andrea
    Menegatti, Benedetta
    Gentilli, Sergio
    Baroffio, Paolo
    Buccianti, Piero
    Balestri, Riccardo
    Ceccarelli, Cristina
    Torri, Valter
    Cavaliere, Davide
    Solaini, Leonardo
    Ercolani, Giorgio
    Traverso, Elena
    Fusco, Vittorio
    Rossi, Maura
    Priora, Fabio
    Numico, G.
    Franzone, Paola
    Orecchia, Sara
    BMC CANCER, 2019, 19 (01)
  • [50] The effect of adjuvant chemotherapy on survival and recurrence after curative rectal cancer surgery in patients who are histologically node negative after neoadjuvant chemoradiotherapy
    Baird, D. L. H.
    Denost, Q.
    Simillis, C.
    Pellino, G.
    Rasheed, S.
    Kontovounisios, C.
    Tekkis, P. P.
    Rullier, E.
    COLORECTAL DISEASE, 2017, 19 (11) : 980 - 986